- Clinical-stage biotech Anavex Life Sciences ( NASDAQ: AVXL ) added ~7% in early pre-market trading Monday after the company disclosed results to highlight the impact of its lead candidate ANAVEX2-73 on the neurodegenerative genes of both Alzheimer’s and Parkinson’s disease patients.
- The results were part of a presentation at the ongoing Alzheimer’s Association International Conference (AAIC) being held in San Diego, CA.
- The genetic data in patients who were part of the company’s Phase 2 ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) study suggested ANAVEX2-73 “significantly restored” the expression levels of pathological neurodegenerative genes, the company said.
- According to Anavex ( AVXL ), “ANAVEX2-73 singularly impacted expression levels of these genes in multiple pathways by the pathological down-regulation of genes in both Alzheimer’s (p<0.005) and Parkinson’s disease (p<0.005) and other degenerative diseases (p<0.005).”
- In June 2021, Anavex ( AVXL ) shares gained after the company disclosed results from the Phase 2 trial for ANAVEX2-73 in PDD.
For further details see:
Anavex gains on the effect of Alzheimer’s drug on genes